Easton Pharmaceuticals Announces it has Reached a Manufacturing Agreement for the Companys OTC Products; Advances Timetable for Product Launch
TORONTO, ON, Canada, via ETELIGIS INC., 08/14/2014 - - Easton Pharmaceuticals (OTC Pink: EAPH) (PINKSHEETS: EAPH) announces they have sourced out, come to terms and agreed to enter into an agreement with a manufacturing partner for the North American Market and is finalizing a manufacturing Agreement for the Latin American market. Company advances timetable towards its OTC product launches.
Easton Pharmaceuticals has agreed and come to terms with a GMP certified manufacturer located in Toronto, Canada, who will manufacture and supply the U.S. and Canadian markets. Pricing has been determined to be on par with Mexican manufacturers, but the company believes quality control can be better managed in local jurisdictions. Final agreements with the manufacturing company are being drafted who have manufactured and packaged dozens of products for various companys across North America. In addition, Easton has entered into negotiations with other companies for distribution of its OTC products and is close to finalizing an agreement to allow for the marketing and sale of the companys products to commence sometime in the very near term. A formal announcement on the North American manufacturing partner and what we believe to be significant developments involving a distribution partner on our OTC products and other well sought after products within the medical marijuana industry, is anticipated sometime within the next 2 to 3 weeks.
It is expected that the Latin and South American efforts, namely the country of Mexico will still have its manufacturing realized in Mexico. BMV Medica, and Dr. Daniel Bagi, a consultant for Easton Pharmaceuticals have reached an agreement in principle with a manufacturer in Mexico. Initial discussions with another FDA approved manufacturer in Mexico were canceled due to pricing dis-agreements with the company. As previously announced, Easton will be using BMV Medica for its distribution of various products in Mexico and Latin American markets
Carla Pepe, CEO of Easton Pharmaceuticals, commented Although the launch of Viorra and our other OTC products have recently taken a bit of a back seat to our medical marijuana initiatives, much of the ground work has been laid out where the company now feels it should now move towards manufacturing, marketing and distribution in a diligent and expeditious manner. We anticipate positive announcements will soon be forthcoming that will demonstrate our commitment to our OTC products in conjunction with our medical marijuana initiatives.
